Key facts
- Intelliseq’s last known valuation is $4.2M (Oct 2022).
- It has raised $6.8M; the latest was Later Stage VC ($4.6M) in Feb 2025.
- Notable investors include European Union, CobinAngels, Google Accelerator, StartSmart CEE, Tadeusz Wesołowsk — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Intelliseq
- ·The full record, as it builds
Funding rounds
No funding rounds for Intelliseq are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Intelliseq
Developer of genome informatics designed to provide development in pharmacogenomics and transcriptomics. The company's services include creating novel algorithms and bioinformatics tools to assist in next-generation sequencing, data analysis, bioinformatics, and consulting, enabling scientific researchers to develop the diagnosis process.
- Sector
- Healthcare
- HQ
- Krakow, Poland
- Founded
- 2014
- Employees
- 17
- Website
- intelliseq.com/
- Ownership
- Privately Held (backing)
Intelliseq doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Intelliseq shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Intelliseq in its N-PORT filings yet. We sweep new filings monthly.